Results 191 to 200 of about 6,038,565 (279)

Incorporating genetics and genetic counselling in neurology clinics: a survey of neurologists' perceptions and current practices. [PDF]

BMJ Neurol Open
Gorman M, Maynard L, Horak H, Schaibley V.   +3 more
europepmc   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

The Red Flags Were Missing, the Indication Was Not: Genetic Testing in Heart Failure and Cardiomyopathy. [PDF]

Methodist Debakey Cardiovasc J
Bakr Salama A.
europepmc   +1 more source

Spatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers

Molecular Oncology, EarlyView.
Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...
Adrien Tourneur, Joel Rodrigues Vitória, Manuel Saiselet, Ligia Craciun, Denis Larsimont, Anne Lefort, Frédérick Libert, Carine Maenhaut, Sabine Costagliola, Maxime Tarabichi, Mirian Romitti, Vincent Detours   +11 more
wiley   +1 more source

National Essential Diagnostics List development as an opportunity to expand frontline diagnostic testing at barangay health stations in the Philippines. [PDF]

Trop Med Health
Kanamori S, Evangelista NM, Egami Y, Marayag NG, Cruz-Yañez S, Dela Resma Villanueva AF, Uechi M, Kiyohara H, Dolor MKYD, Ramones RAJ, Duazo AA, Fujita M.   +11 more
europepmc   +1 more source

Hazardous and industrial solid waste testing ... symposium

, 1983
American Society for Testing and Materials, Symposium on Hazardous and Industrial Solid Waste Testing   +1 more
core  

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

EMPA activities 2003. Report on technical and scientific activities

, 2003
Swiss Federal Laboratories for Materials Testing and Research (author)
core   +1 more source

Uptake and feasibility of task-shifting of Xpert MTB/RIF Ultra testing from laboratory technicians to nurses to increase access and reduce time to results: a multicountry mixed method research. [PDF]

BMJ Glob Health
Ngu EM, Basant J, Bhatta B, Huyen Ton Nu Nguyet M, Lounnas M, Kaitano RM, N'Guessan MS, Kasakwa KM, Manhiça EMA, Yin S, Mugisha JR, Ouassa TD, Taguebue JV, Moh R, Breton G, Mwanga-Amumpere J, Borand L, Chabala C, Khosa C, Wobudeya E, Marcy O, Orne-Gliemann J, Bonnet M, TB Speed study group.   +23 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source